Healthcare · NSE/BSE: TORNTPHARM
Torrent Pharmaceuticals Limited
Pharmaceuticals
Market Cap ₹1.51L Cr
Verdict: High
Quality Scores
Multi-Bagger
84/100
Compounder Quality
91/100
Management Credibility
88/100
Governance
92/100
Cash Flow Quality
95/100
AI Summary
Torrent Pharmaceuticals is a leading Indian branded generics player with a dominant position in chronic therapeutic segments. Over the last decade, the company has transitioned from a cyclical US-focused model to a high-margin branded business in India and Brazil, which now contributes 74% of revenue. Despite a high debt-led acquisition of Curatio in recent years and the massive spike in Mar 2026 borrowings for likely strategic expansion, the core business maintains an industry-leading operating margin of 30-33%. The company's focus on specialty drugs and high medical representative…
Top Opportunities
- Consistent margin expansion over 10 years
- Superior ROE profile exceeding 25%
- High quality of earnings (CFO usually > Net Profit)
Top Risks
- High Stock P/E relative to median sector
- Significant debt increase projected for 2026
- Dependence on Indian regulatory environment
Latest report: Read the annual report summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.